Clínica Baviera, S.A. (BME:CBAV)
Spain · Delayed Price · Currency is EUR 59.00
-1.20 (-1.99%)
Aug 27, 2026, 5:35 PM CET
Clínica Baviera Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 320.67 | 304.91 | 265.72 | 227.07 | 198.45 | 173.25 | |
Revenue Growth | 11.03% | 14.75% | 17.02% | 14.42% | 14.55% | 41.28% |
Cost of Revenue | 160.83 | 153.93 | 133.18 | 115.1 | 96.55 | 84.05 |
Gross Profit | 159.84 | 150.98 | 132.54 | 111.97 | 101.9 | 89.2 |
Selling, General & Admin | 17.78 | 17.78 | 13.93 | 12.09 | 11.69 | 9.87 |
Amortization of Goodwill & Intangibles | 23.9 | 23.9 | 20.88 | - | 15 | - |
Other Operating Expenses | 51.53 | 48.67 | 42.08 | 32.86 | 33.25 | 25.77 |
Operating Expenses | 95.26 | 90.34 | 76.89 | 61.93 | 59.94 | 49.73 |
Operating Income | 64.58 | 60.64 | 55.65 | 50.04 | 41.96 | 39.46 |
Interest Expense | -2.62 | -2.28 | -1.22 | -0.57 | -0.42 | -0.46 |
Interest & Investment Income | 1.49 | 1.52 | 0.3 | 0.15 | 0.07 | 0 |
Earnings From Equity Investments | 0.04 | 0.04 | -0.02 | -0.01 | -0.06 | -0.03 |
Currency Exchange Gain (Loss) | -0.01 | -0.08 | 0.04 | 0.01 | -0 | -0 |
Other Non Operating Income (Expenses) | 0.96 | - | - | 0.07 | -0.4 | -0.04 |
EBT Excluding Unusual Items | 64.45 | 59.84 | 54.74 | 49.68 | 41.15 | 38.93 |
Gain (Loss) on Sale of Investments | 0.37 | 0.37 | 1.22 | - | - | - |
Asset Writedown | -0.04 | -0.1 | 0.03 | -0.03 | -0.47 | -0.03 |
Pretax Income | 64.78 | 60.11 | 55.99 | 49.65 | 40.68 | 38.9 |
Income Tax Expense | 17.98 | 17.18 | 14.86 | 12.92 | 10.53 | 10.97 |
Earnings From Continuing Operations | 46.8 | 42.94 | 41.14 | 36.73 | 30.15 | 27.93 |
Minority Interest in Earnings | -0.85 | -0.87 | -0.93 | -0.76 | -0.63 | -0.54 |
Net Income | 45.95 | 42.06 | 40.21 | 35.97 | 29.52 | 27.39 |
Net Income to Common | 45.95 | 42.06 | 40.21 | 35.97 | 29.52 | 27.39 |
Net Income Growth | 17.52% | 4.62% | 11.77% | 21.86% | 7.77% | 96.46% |
Shares Outstanding (Basic) | 16 | 16 | 16 | 16 | 16 | 16 |
Shares Outstanding (Diluted) | 16 | 16 | 16 | 16 | 16 | 16 |
Shares Change | -0.04% | 0.08% | -1.85% | - | - | 0.01% |
EPS (Basic) | 2.87 | 2.63 | 2.51 | 2.21 | 1.81 | 1.68 |
EPS (Diluted) | 2.87 | 2.63 | 2.51 | 2.21 | 1.81 | 1.68 |
EPS Growth | 17.57% | 4.54% | 13.88% | 21.86% | 7.77% | 96.43% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 46.32 | 46.83 | 36 | 35.13 | 39.35 | 36.28 |
Free Cash Flow Per Share | 2.89 | 2.92 | 2.25 | 2.15 | 2.41 | 2.23 |
Dividend Per Share | 1.570 | 1.570 | 1.570 | 1.570 | 1.300 | 1.030 |
Dividend Growth | 0% | 0% | 0% | 20.77% | 26.21% | 86.59% |
Gross Margin | 49.85% | 49.52% | 49.88% | 49.31% | 51.35% | 51.49% |
Operating Margin | 20.14% | 19.89% | 20.94% | 22.04% | 21.14% | 22.78% |
Profit Margin | 14.33% | 13.79% | 15.13% | 15.84% | 14.88% | 15.81% |
Free Cash Flow Margin | 14.45% | 15.36% | 13.55% | 15.47% | 19.83% | 20.94% |
EBITDA | 88.77 | 82.77 | 75.63 | 66.5 | 56.76 | 53.35 |
EBITDA Margin | 27.68% | 27.15% | 28.46% | 29.29% | 28.60% | 30.80% |
D&A For EBITDA | 24.19 | 22.13 | 19.98 | 16.46 | 14.8 | 13.89 |
EBIT | 64.58 | 60.64 | 55.65 | 50.04 | 41.96 | 39.46 |
EBIT Margin | 20.14% | 19.89% | 20.94% | 22.04% | 21.14% | 22.78% |
Effective Tax Rate | 27.75% | 28.57% | 26.53% | 26.02% | 25.89% | 28.19% |
Advertising Expenses | - | 15.09 | 12.14 | 10.31 | 9.86 | 8.42 |